NextCure (NASDAQ:NXTC) Major Shareholder Buys $17,050.00 in Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc acquired 3,410 shares of the company’s stock in a transaction on Wednesday, July 29th. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $17,050.00. Following the completion of the purchase, the insider directly owned 393,266 shares in the company, valued at $1,966,330. This trade represents a 0.87% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, July 28th, Adar1 Capital Management, Llc bought 6,400 shares of NextCure stock. The stock was purchased at an average price of $4.95 per share, with a total value of $31,680.00.
• On Monday, July 27th, Adar1 Capital Management, Llc bought 7,798 shares of NextCure stock. The stock was purchased at an average price of $5.00 per share, with a total value of $38,990.00.

NextCure Stock Down 17.7%

Shares of NASDAQ:NXTC opened at $4.14 on Friday. NextCure, Inc. has a fifty-two week low of $1.55 and a fifty-two week high of $15.74. The firm’s 50-day simple moving average is $3.49 and its 200-day simple moving average is $8.68. The company has a market cap of $14.95 million, a price-to-earnings ratio of -0.24 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.10) by $0.23. On average, research analysts forecast that NextCure, Inc. will post -7.89 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on NXTC shares. Wall Street Zen downgraded NextCure from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings downgraded NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of NextCure in a report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $19.00.

Institutional Investors Weigh In On NextCure

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its stake in shares of NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after acquiring an additional 3,636 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of NextCure by 18.7% in the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after acquiring an additional 5,300 shares during the period. Marshall Wace LLP purchased a new position in NextCure in the 4th quarter valued at approximately $160,000. Millennium Management LLC purchased a new position in NextCure in the 4th quarter valued at approximately $185,000. Finally, Affinity Asset Advisors LLC raised its holdings in NextCure by 28.9% during the fourth quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock worth $3,509,000 after purchasing an additional 55,412 shares during the last quarter. 42.65% of the stock is currently owned by institutional investors and hedge funds.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.